Exoxemis

A biopharmaceutical research and development company, develops haloperoxidase products for prevention and treatment of serious infections.

Microbiological infection caused by bacteria, viruses, fungi, and prions is an important concern in a range of healthcare sectors affecting human health and well-being. Safe and effective microbicidal products are especially critical today, when antimicrobial resistance and the potential for the rapid spread of pathogens have become public-health issues in countries throughout the world. For 20 years, Exoxemis, Inc. has been the leader in the development of broad-spectrum haloperoxidase-based products for use in high-value product areas, including a biological entity for use in high morbidity/mortality applications. They are committed to integrating their technology with the intellectual, financial, and commercial strengths of prospective partners to develop innovative products and long-term relationships.